Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosusIndra Adrianto, Patrick M. Gaffney, Jennifer A. Kelly et al.|Nature Genetics|2011Cited by 284
Real-world study of chemotherapy plus immunotherapy versus chemotherapy alone as neoadjuvant treatment guided bladder-sparing therapy for localized muscle-invasive bladder cancer.Yali Shen, Tianhai Lin, Feng Wen et al.|Journal of Clinical Oncology|2022Cited by 7
A multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03).Feng Wen, Yali Shen, Tianhai Lin et al.|Journal of Clinical Oncology|2025Cited by 3
Long-term results of a phase 2 study of neoadjuvant chemotherapy combined with tislelizumab followed by radiotherapy for bladder-preserving treatment in selected high-risk/locally advanced muscle invasive urothelial bladder cancer (HOPE-02).Feng Wen, Yali Shen, Tianhai Lin et al.|Journal of Clinical Oncology|2025Cited by 2